机构:[1]Endocrinology Department, The Second Hospital of Hebei Medical University, No.215 Heping West Road, Shijiazhuang, 050000, People's Republic of China.[2]General Medical Department, The Fourth Hospital of Hebei Medical University, No.12 Jiankang Road, Shijiazhuang, 050000, People's Republic of China.河北医科大学第四医院[3]Medical Department, The Second Hospital of Hebei Medical University, No.215 Heping West Road, Shijiazhuang 050000, People’s Republic of China.
This study was supported by the grant from the Hebei Province medical science research project plan (No.
20230458).
语种:
外文
PubmedID:
中科院分区:
出版当年[2025]版:
大类|3 区综合性期刊
小类|3 区综合性期刊
最新[2025]版:
大类|3 区综合性期刊
小类|3 区综合性期刊
第一作者:
第一作者机构:[1]Endocrinology Department, The Second Hospital of Hebei Medical University, No.215 Heping West Road, Shijiazhuang, 050000, People's Republic of China.
通讯作者:
推荐引用方式(GB/T 7714):
Liu Jing,Meng Lingzhen,Liu Zhihong,et al.Identification of HDAC9 and ARRDC4 as potential biomarkers and targets for treatment of type 2 diabetes[J].Scientific Reports.2024,14(1):7083.doi:10.1038/s41598-024-57794-5.
APA:
Liu Jing,Meng Lingzhen,Liu Zhihong,Lu Ming&Wang Ruiying.(2024).Identification of HDAC9 and ARRDC4 as potential biomarkers and targets for treatment of type 2 diabetes.Scientific Reports,14,(1)
MLA:
Liu Jing,et al."Identification of HDAC9 and ARRDC4 as potential biomarkers and targets for treatment of type 2 diabetes".Scientific Reports 14..1(2024):7083